Skip to main content

Table 1 Trial Characteristics

From: Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups

  Irinotecan-based Oxaliplati n-based Fluorouracil alone  
Study Hurwitz, 2004 (AVF2107) [26] Stathopoulos, 2010 [24] Saltz, 2008 (NO16966) [25] Kabinnavar, 2003 [21] Kabinnavar, 2005 [22] Tebutt, 2010 (MAX) [23]
No. of patients (placebo/bev) 411/402 108/114 701/699 36/68 105/104 156/156
Phase III III III II II III
Randomization Adequate Adequate Adequate Adequate Adequate Unclear
Study Population First-line First-line First-line First-line First-line, elderly First-line, elderly
ITT Analysis Yes No Yes No Yes Yes
Blinding Yes No Yes No Yes Yes
Multicentric Yes No Yes Yes Yes Yes
Alpha error Yes Yes Yes NS Yes Yes
Beta error Yes Yes Yes NS Yes Yes
Withdrawals NS Described Described Described Described Described
Regimens Saltz IFL Irino 135 mg/m2 + 5 FU 500 mg/m2 + LV 200 mg/m2 every 21 d XELOX or FOLFOX4 Roswell- Park Roswell- Park Capecitabine
Bev schedule 5 mg/kg every 14 d 7.5 mg/kg every 21 d 7.5 mg/kg every 21 d (XELOX) or 5 mg/kg every 14 d (FOLFOX4) 10 mg/kg every 14 d (32 patients) 5 mg/kg every 14 d (33 patients) 5 mg/kg every 14 d 7.5 mg/kg every 21 d
Maintenance Until Progression Until Progression Until Progression 48 Weeks Until Progression Until Progression
Sponsor Industry NS Industry NS Public Public/Industry
  1. Description of the main trials' characteristics and details prompt to bias.
  2. Abbreviations: 5FU: fluorouracil; bev: Bevacizumab; d: days; Irino: Irinotecan; ITT: Intention to Treat; LV: leucovorin; NS: not stated.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us